Page 1396 - Williams Hematology ( PDFDrive )

1370 Part X: Malignant Myeloid Diseases Chapter 87: Myelodysplastic Syndromes 1371

517. Blum W, Garzon R, Klisovic RB, et al: Clinical response and miR-29b predictive signif- 544. de la Rubia J, Regadera A, Martin G, et al: FLAG-IDA regimen (fludarabine, cytarabine,
icance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl idarubicin, and G-CSF) in the treatment of patients with high-risk myeloid malignan-
Acad Sci U S A 107(16):7473–7478, 2010. cies. Leuk Res 26(8):725–730, 2002.
518. Blum W: How much? How frequent? How long? A clinical guide to new therapies in 545. Marcondes M, Deeg HJ: Hematopoietic cell transplantation for patients with myelo-
myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2010:314–321, dysplastic syndromes (MDS): When, how and for whom? Best Pract Res Clin Haematol
2010. 21(1):67–77, 2008.
519. Daskalakis M, Nguyen TT, Nguyen C, et al: Demethylation of a hypermethylated P15/ 546. Oliansky DM, Antin JH, Bennett JM, et al: The role of cytotoxic therapy with hemato-
INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine poietic stem cell transplantation in the therapy of myelodysplastic syndromes: An
(decitabine) treatment. Blood 100(8):2957–2964, 2002. evidence-based review. Biol Blood Marrow Transplant 15(2):137–172, 2009.
520. Shen L, Kantarjian H, Guo Y, et al: DNA methylation predicts survival and response to 547. Hahn T, McCarthy PL Jr, Hassebroek A, et al: Significant improvement in survival after
therapy in patients with myelodysplastic syndromes. J Clin Oncol 28(4):605–613, 2010. allogeneic hematopoietic cell transplantation during a period of significantly increased
521. Klisovic RB, Stock W, Cataland S, et al: A phase I biological study of MG98, an oli- use, older recipient age, and use of unrelated donors. J Clin Oncol 31(19):2437–2449,
godeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk 2013.
myelodysplasia and acute myeloid leukemia. Clin Cancer Res 14(8):2444–2449, 2008. 548. Cutler CS, Lee SJ, Greenberg P, et al: A decision analysis of allogeneic bone marrow
522. Gerds AT, Gooley TA, Estey EH, et al: Pretransplantation therapy with azacitidine vs. transplantation for the myelodysplastic syndromes: Delayed transplantation for low-
induction chemotherapy and posttransplantation outcome in patients with MDS. Biol risk myelodysplasia is associated with improved outcome. Blood 104(2):579–585, 2004.
Blood Marrow Transplant 18(8):1211–1218, 2012. 549. Koreth J, Pidala J, Perez WS, et al: Role of reduced-intensity conditioning allogeneic
523. Quintas-Cardama A, Santos FP, Garcia-Manero G. Histone deacetylase inhibitors for hematopoietic stem-cell transplantation in older patients with de novo myelodysplas-
the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia tic syndromes: An international collaborative decision analysis. J Clin Oncol 31(21):
25(2):226–235, 2011. 2662–2670, 2013.
524. Prebet T, Vey N: Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. 550. Castro-Malaspina H, Harris RE, Gajewski J, et al: Unrelated donor marrow transplanta-
Expert Opin Investig Drugs 20(2):287–295, 2011. tion for myelodysplastic syndromes: Outcome analysis in 510 transplants facilitated by
525. Kuendgen A, Bug G, Ottmann OG, et al: Treatment of poor-risk myelodysplastic syn- the National Marrow Donor Program. Blood 99(6):1943–1951, 2002.
dromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic 551. Armand P, Kim HT, DeAngelo DJ, et al: Impact of cytogenetics on outcome of de novo
acid. Clin Epigenetics 2(2):389–399, 2011. and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow
526. Voso MT, Santini V, Finelli C, et al: Valproic acid at therapeutic plasma levels may Transplant 13(6):655–664, 2007.
increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer 552. Warlick ED, Cioc A, Defor T, et al: Allogeneic stem cell transplantation for adults with
Res 15(15):5002–5007, 2009. myelodysplastic syndromes: Importance of pretransplant disease burden. Biol Blood
527. Garcia-Manero G, Assouline S, Cortes J, et al: Phase 1 study of the oral isotype specific Marrow Transplant 15(1):30–38, 2009.
histone deacetylase inhibitor MGCD0103 in leukemia. Blood 112(4):981–989, 2008. 553. Chang C, Storer BE, Scott BL, et al: Hematopoietic cell transplantation in patients with
528. Ottmann OG, DeAngelo DJ, Garcia-Manero G, et al: Determination of a phase II dose myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic
of panobinostat in combination with 5-azacitidine in patients with myelodysplastic syndrome: Similar outcomes in patients with de novo disease and disease following
syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia. Blood (ASH prior therapy or antecedent hematologic disorders. Blood 110(4):1379–1387, 2007.
Annu Meet Abstr) 118:459, 2011. 554. Kroger N, Brand R, van Biezen A, et al: Risk factors for therapy-related myelodysplastic
529. Cashen A, Juckett M, Jumonville A, et al: Phase II study of the histone deacetylase syndrome and acute myeloid leukemia treated with allogeneic stem cell transplanta-
inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS). tion. Haematologica 94(4):542–549, 2009.
Ann Hematol 91(1):33–38, 2012. 555. Scott BL, Park JY, Deeg HJ, et al: Pretransplant neutropenia is associated with poor-risk
530. Sekeres MA, O’Keefe C, List AF, et al: Demonstration of additional benefit in adding cytogenetic features and increased infection-related mortality in patients with myelo-
lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes. dysplastic syndromes. Biol Blood Marrow Transplant 14(7):799–806, 2008.
Am J Hematol 86(1):102–103, 2011. 556. Platzbecker U, Schetelig J, Finke J, et al: Allogeneic hematopoietic cell transplantation
531. Silverman LR, Verma A, Odchimar-Reissig R, et al: Abstract #386: A phase II trial of in patients aged 60–70 years with de novo high-risk myelodysplastic syndrome or sec-
epigenetic modulators vorinostat in combination with azacitidine (azaC) in patients ondary acute myelogenous leukemia: Comparison with patients lacking donors who
with the myelodysplastic syndrome (MDS): Initial results of study 6898 of the New received azacitidine. Biol Blood Marrow Transplant 18(9):1415–1421, 2012.
York Cancer Consortium. Blood (ASH Annu Meet Abstr) 122(11a). 557. Kim DY, Lee JH, Park YH, et al: Feasibility of hypomethylating agents followed by allo-
532. Garcia-Manero G, Estey E, Jabbour E, et al: Final report of a phase II study of 5- geneic hematopoietic cell transplantation in patients with myelodysplastic syndrome.
azacitidine and vorinostat in patients with newly diagnosed myelodysplastic syndrome Bone Marrow Transplant 47(3):374–379, 2012.
or acute myelogenous leukemia not eligible for clinical trials because poor performance 558. Platzbecker U, Wermke M, Radke J, et al: Azacitidine for treatment of imminent relapse
and presence of other comorbidities. Blood (ASH Annu Meet Abstr) 118:608, 2011. in MDS or AML patients after allogeneic HSCT: Results of the RELAZA trial. Leukemia
533. Prebet T, Gore SD, Sun Z, et al: Prolonged administration of azacitidine with or without 26(3):381–389, 2012.
entinostat increases rate of hematologic normalization for myelodysplastic syndrome 559. Luger SM, Ringden O, Zhang MJ, et al: Similar outcomes using myeloablative vs
and acute myeloid leukemia with myelodysplasia-related changes: Results of the US reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone
Leukemia Intergroup Trial E1905. J Clin Oncol. 20;32(12):1242-8, 2014. Marrow Transplant 47(2):203–211, 2012.
534. Prebet T, Gore SD, Esterni B, et al: Outcome of high-risk myelodysplastic syndrome 560. Pollyea DA, Artz AS, Stock W, et al: Outcomes of patients with AML and MDS who
after azacitidine treatment failure. J Clin Oncol 29(24):3322–3327, 2011. relapse or progress after reduced intensity allogeneic hematopoietic cell transplanta-
535. Jabbour E, Garcia-Manero G, Batty N, et al: Outcome of patients with myelodysplastic tion. Bone Marrow Transplant 40(11):1027–1032, 2007.
syndrome after failure of decitabine therapy. Cancer 116(16):3830–3834, 2010. 561. Campregher PV, Gooley T, Scott BL, et al: Results of donor lymphocyte infusions for
536. Guillermo Garcia-Manero, Pierre Fenaux, Aref Al-Kali, et al: Overall survival and subgroup relapsed myelodysplastic syndrome after hematopoietic cell transplantation. Bone
analysis from a randomized phase III study of intravenous rigosertib versus best supportive Marrow Transplant 40(10):965–971, 2007.
care (BSC) in patients (pts) with higher-risk myelodysplastic ssyndrome (HR-MDS) after 562. de Witte T, Oosterveld M, Muus P: Autologous and allogeneic stem cell transplantation
failure of hypomethylating agents (HMAs). Blood (ASH Annu Meet Abstr) 163(124). for myelodysplastic syndrome. Blood Rev 21(1):49–59, 2007.
537. Komrokji RS, Raza A, Lancet JE, et al: Phase I clinical trial of oral rigosertib in patients 563. de Witte T, Suciu S, Brand R, et al: Autologous stem cell transplantation in myelodys-
with myelodysplastic syndromes. Br J Haematol 162(4):517–524, 2013. plastic syndromes. Semin Hematol 44(4):274–277, 2007.
538. Singh V, Sharma P, Capalash N: DNA methyltransferase-1 inhibitors as epigenetic ther- 564. de Witte T, Van Biezen A, Hermans J, et al: Autologous bone marrow transplantation
apy for cancer. Curr Cancer Drug Targets 13(4):379–399, 2013. for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia follow-
539. Coral S, Parisi G, Nicolay HJ, et al: Immunomodulatory activity of SGI-110, a ing MDS. Chronic and Acute Leukemia Working Parties of the European Group for
5-aza-2′-deoxycytidine-containing demethylating dinucleotide. Cancer Immunol Blood and Marrow Transplantation. Blood 90(10):3853–3857, 1997.
Immunother 62(3):605–614, 2013. 565. Wattel E, Solary E, Leleu X, et al: A prospective study of autologous bone marrow or
540. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al: Azacitidine prolongs overall survival peripheral blood stem cell transplantation after intensive chemotherapy in myelodys-
compared with conventional care regimens in elderly patients with low bone marrow plastic syndromes. Groupe Francais des Myelodysplasies. Group Ouest-Est d’etude des
blast count acute myeloid leukemia. J Clin Oncol 28(4):562–569, 2010. Leucemies aigues myeloides. Leukemia 13(4):524–529, 1999.
541. Beran M, Shen Y, Kantarjian H, et al: High-dose chemotherapy in high-risk myelo- 566. Viola A, Falco C, D’Elia R, et al: An antecedent diagnosis of refractory anemia with
dysplastic syndrome: Covariate-adjusted comparison of five regimens. Cancer 92(8): excess blasts has no influence on mobilization of peripheral blood stem cells and
1999–2015, 2001. hematopoietic recovery after autologous stem cell transplantation in acute myeloid
542. Knipp S, Hildebrand B, Kundgen A, et al: Intensive chemotherapy is not recommended leukemia. Eur J Haematol 78(1):41–47, 2007.
for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leu- 567. Burnett AK, Milligan D, Prentice AG, et al: A comparison of low-dose cytarabine and
kemia with high-risk karyotypes. Cancer 110(2):345–352, 2007. hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and
543. Cortes J, Kantarjian H, Albitar M, et al: A randomized trial of liposomal daunorubicin high-risk myelodysplastic syndrome in patients not considered fit for intensive treat-
and cytarabine versus liposomal daunorubicin and topotecan with or without thalido- ment. Cancer 109(6):1114–1124, 2007.
mide as initial therapy for patients with poor prognosis acute myelogenous leukemia or 568. Ogata K, Nomura T: Application of low-dose etoposide therapy for myelodysplastic
myelodysplastic syndrome. Cancer 97(5):1234–1241, 2003. syndromes. Leuk Lymphoma 12(1–2):35–39, 1993.

Kaushansky_chapter 87_p1341-1372.indd 1371 9/21/15 11:06 AM